

Title (en)  
MULTISPECIFIC ANTIBODY

Title (de)  
MULTISPEZIFISCHER ANTIKÖRPER

Title (fr)  
ANTICORPS MULTI-SPÉCIFIQUE

Publication  
**EP 3915580 A1 20211201 (EN)**

Application  
**EP 20177337 A 20200529**

Priority  
EP 20177337 A 20200529

Abstract (en)  
The present invention relates to a multispecific antibody comprising two antibody-based binding domains, which specifically binds to mesothelin (MSLN-BD); and at least one antibody-based binding domain, which specifically binds to CD3 (CD3-BD); wherein said multispecific antibody does not comprise an immunoglobulin Fc region polypeptide, and wherein each of said MSLN-BD binds to mesothelin (MSLN) with a monovalent dissociation constant ( $K_{D</sub>$ ) in the range of from 0.5 to 20 nM, when measured by SPR. The present invention further relates to nucleic acid sequence(s) encoding said multispecific antibody, vector(s) comprising said nucleic acid sequence(s), host cell(s) comprising said nucleic acid sequence(s) or said vector(s), and a method of producing said multispecific antibody. Additionally, the present invention relates to pharmaceutical compositions comprising said multispecific antibody and methods of use thereof.

IPC 8 full level  
**A61K 39/395** (2006.01); **C07K 16/28** (2006.01); **C07K 16/30** (2006.01)

CPC (source: EP)  
**A61K 39/395** (2013.01); **C07K 16/28** (2013.01); **C07K 16/2809** (2013.01); **C07K 16/30** (2013.01); **A61K 2039/505** (2013.01); **C07K 2317/24** (2013.01); **C07K 2317/31** (2013.01); **C07K 2317/56** (2013.01); **C07K 2317/565** (2013.01); **C07K 2317/92** (2013.01)

Citation (applicant)  
• US 6075181 A 20000613 - KUCHERLAPATI RAJU [US], et al  
• US 6150584 A 20001121 - KUCHERLAPATI RAJU [US], et al  
• US 5766886 A 19980616 - STUDNICKA GARY M [US], et al  
• EP 0486525 A1 19920527 - CEMU BIOTEKNIK AB [SE]  
• US 6267964 B1 20010731 - NYGREN PER AAKE [SE], et al  
• WO 2004001064 A2 20031231 - DYAX CORP [US], et al  
• WO 02076489 A1 20021003 - DYAX CORP [US], et al  
• WO 0145746 A2 20010628 - GENENTECH INC [US], et al  
• WO 2004003019 A2 20040108 - DOMANTIS LTD [GB], et al  
• WO 2008096158 A2 20080814 - DOMANTIS LTD [GB], et al  
• WO 2005118642 A2 20051215 - DOMANTIS LTD [GB], et al  
• WO 2006059105 A2 20060608 - HEALTH PROT AGENCY [GB], et al  
• WO 2011006915 A2 20110120 - GLAXO GROUP LTD [GB], et al  
• WO 2009040562 A1 20090402 - UCB PHARMA SA [BE], et al  
• WO 2010035012 A1 20100401 - UCB PHARMA SA [BE], et al  
• WO 2011086091 A1 20110721 - UCB PHARMA SA [BE], et al  
• WO 2019057787 A1 20190328 - NUMAB INNOVATION AG [CH]  
• WO 2016202457 A1 20161222 - NUMAB AG [CH]  
• EP 0404097 A2 19901227 - BEHRINGWERKE AG [DE]  
• WO 9301161 A1 19930121 - PFIZER LTD [GB], et al  
• WO 9957150 A2 19991111 - DEUTSCHES KREBSFORSCH [DE], et al  
• US 5260203 A 19931109 - LADNER ROBERT C [US], et al  
• US 5455030 A 19951003 - LADNER ROBERT C [US], et al  
• US 4881175 A 19891114 - LADNER ROBERT C [US]  
• US 5132405 A 19920721 - HUSTON JAMES S [US], et al  
• US 5091513 A 19920225 - HUSTON JAMES S [US], et al  
• US 5476786 A 19951219 - HUSTON JAMES S [US], et al  
• US 5013653 A 19910507 - HUSTON JAMES S [US], et al  
• US 5258498 A 19931102 - HUSTON JAMES S [US], et al  
• US 5482858 A 19960109 - HUSTON JAMES S [US], et al  
• US 4458066 A 19840703 - CARUTHERS MARVIN H [US], et al  
• EP 2018064630 W 20180604  
• EP 20164913 A 20200323  
• EP 19206959 A 20191104  
• WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546  
• HOOGENBOOMWINTER, J. MOL. BIOL, vol. 222, 1991, pages 581  
• AL-LAZIKANI ET AL., JMB, vol. 273, 1997, pages 927 - 948  
• LEFRANC, M.-P., THE IMMUNOLOGIST, vol. 7, 1999, pages 132 - 136  
• LEFRANC, M.-P. ET AL., DEV. COMP. IMMUNOL., vol. 27, 2003, pages 55 - 77  
• HONEGGERPLUCKTHUN, J. MOL. BIOL., vol. 309, 2001, pages 657 - 670  
• LIU, M A ET AL., PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 8648  
• BOEMER ET AL., J. IMMUNOL, vol. 147, no. 1, 1991, pages 86 - 95  
• VAN DIJKVAN DE WINKEL, CURR. OPIN. PHARMACOL, vol. 5, 2001, pages 368 - 74  
• LI ET AL., PROC. NATL. ACAD. SCI. USA, vol. 103, 2006, pages 3557 - 3562  
• MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 6851 - 6855  
• MORRISONOI, ADV. IMMUNOL., vol. 44, 1988, pages 65 - 92  
• VERHOEYEN ET AL., SCIENCE, vol. 239, 1988, pages 1534 - 1536  
• PADLAN, MOLEC. IMMUN., vol. 28, 1991, pages 489 - 498

- PADLAN, MOLEC. IMMUN., vol. 31, 1994, pages 169 - 217
- MEDASAN ET AL., J. IMMUNOL., vol. 158, 1997, pages 2211 - 2217
- SUGIO, PROTEIN ENG., vol. 12, 1999, pages 439 - 446
- FANALI, MOLECULAR ASPECTS OF MEDICINE, vol. 33, 2012, pages 209 - 290
- SMITH ET AL., BIOCONJUGATE CHEM., vol. 12, 2001, pages 750 - 756
- HOLT ET AL., PROTEIN ENGINEERING, DESIGN & SELECTION, vol. 21, no. 5, pages 283 - 288
- KNAPPIK ET AL., J. MOL. BIOL., vol. 296, 2000, pages 57 - 86
- EGAN TJ ET AL.: "Novel multi-specific heterodimeric antibody format allowing modular assembly of variable domain fragments", MABS, vol. 9, 2017, pages 68 - 84
- MABS, vol. 9, no. 2, February 2017 (2017-02-01), pages 182 - 212
- HUDSON ET AL., NAT. MED., vol. 9, 2003, pages 129 - 134
- HOLLINGER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448
- FISCHER, N.LEGER, O., PATHOBIOLOGY, vol. 74, 2007, pages 3 - 14
- HORNIG, N.FARBER-SCHWARZ, A., METHODS MOL. BIOL., vol. 907, 2012, pages 713 - 727
- LABRIJN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 110, 2013, pages 5145 - 5150
- DE KRUIF ET AL., BIOTECHNOL. BIOENG., vol. 106, 2010, pages 741 - 750
- ZHU ET AL., CANCER LETT., vol. 86, 1994, pages 127 - 134
- SURESH ET AL., METHODS ENZYMOL., vol. 121, 1986, pages 210 - 228
- YOKOYAMA ET AL.: "Curr. Protoc. Immunol.", 2006
- CHAMESBATY, FEMS MICROBIOL. LETTERS, vol. 189, 2000, pages 1 - 8
- KARPOVSKY ET AL., J. EXP. MED., vol. 160, 1984, pages 1686
- PAULUS, BEHRING INS. MITT., vol. 78, 1985, pages 118 - 132
- BRENNAN ET AL., SCIENCE, vol. 229, 1985, pages 81 - 83
- GLENNIE ET AL., J. IMMUNOL., vol. 139, 1987, pages 2367 - 2375
- BATZER ET AL., NUCLEIC ACID RES., vol. 19, 1991, pages 5081
- OHTSUKA ET AL., J. BIOL. CHEM., vol. 260, 1985, pages 2605 - 2608
- ROSSOLINI ET AL., MOL. CELL. PROBES, vol. 8, 1994, pages 91 - 98
- NARANG ET AL., METH. ENZYMOL., vol. 68, 1979, pages 109
- BEAUCAGE ET AL., TETRA. LETT., vol. 22, 1981, pages 1859
- ROSENFELD ET AL., CELL, vol. 68, 1992, pages 143
- "PCR Protocols: A Guide to Methods and Applications", 1990, ACADEMIC PRESS
- MATTILA ET AL., NUCLEIC ACIDS RES., vol. 19, 1991, pages 967
- ECKERT ET AL., PCR METHODS AND APPLICATIONS, vol. 1, 1991, pages 17
- HARRINGTON ET AL., NAT GENET., vol. 15, 1997, pages 345
- SMITH, ANNU. REV. MICROBIOL., vol. 49, 1995, pages 807
- SCHARF ET AL., RESULTS PROBL. CELL DIFFER., vol. 20, 1994, pages 125
- BITTNER ET AL., METH. ENZYMOL., vol. 153, 1987, pages 516
- WINNACKER: "FROM GENES TO CLONES", 1987, VCH PUBLISHERS
- QUEEN ET AL., IMMUNOL. REV., vol. 89, 1986, pages 49 - 68
- ELLIOT-HARE, CELL, vol. 88, 1997, pages 223
- "Remington: The Science and Practice of Pharmacy", 2000, MACK PUBLISHING CO.
- "Sustained and Controlled Release Drug Delivery Systems", 1978, MARCEL DEKKER, INC.

#### Citation (search report)

- [A] WO 2017055391 A1 20170406 - HOFFMANN LA ROCHE [CH], et al
- [A] US 2017029502 A1 20170202 - RAUM TOBIAS [DE], et al
- [A] WO 2018224443 A1 20181213 - NUMAB INNOVATION AG [CH]
- [A] US 2016340440 A1 20161124 - FANSLOW III WILLIAM CHRISTIAN [US], et al
- [I] RICHARD AUSTIN ET AL: "HPN536, a T cell-engaging, Mesothelin/CD3-specific TriTAC for the treatment of solid tumors IN VITRO PHARMACOLOGY BACKGROUND", AACR ANNUAL MEETING, 14 April 2018 (2018-04-14), XP055742797
- [T] ULRICH BRINKMANN ET AL: "The making of bispecific antibodies", MABS, vol. 9, no. 2, 10 January 2017 (2017-01-10), US, pages 182 - 212, XP055531122, ISSN: 1942-0862, DOI: 10.1080/19420862.2016.1268307
- [A] TEA GUNDE ET AL: "Abstract 1532: A novel, monovalent tri-specific antibody-based molecule that simultaneously modulates PD-L1 and 4-1BB exhibits potent anti-tumoral activity in vivo", IMMUNOLOGY, 1 July 2019 (2019-07-01), GB, pages 1532 - 1532, XP055766584, ISSN: 0019-2805, DOI: 10.1158/1538-7445.AM2019-1532

#### Cited by

EP3988568A1; WO2022084440A2

#### Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

#### Designated extension state (EPC)

BA ME

#### DOCDB simple family (publication)

EP 3915580 A1 20211201; TW 202212355 A 20220401; WO 2021239987 A1 20211202; WO 2021239987 A9 20230202

#### DOCDB simple family (application)

EP 20177337 A 20200529; EP 2021064427 W 20210528; TW 110119667 A 20210531